Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program [CARE DELIVERY]

Conclusion: This experience demonstrates that a program enrolling patients in specific targeted agent clinical trials after NGS can be implemented successfully outside of the NCI-designated cancer program network, with comparable accrual rates. This is important because targetable genes have rare mutation rates and clinical trial accrual after NGS is low.

http://jop.ascopubs.org/cgi/content/short/12/4/e396?rss=1

Source: Journal of Oncology Practice - April 11, 2016 Category: Cancer & Oncology Authors: Mantripragada, K. C., Olszewski, A. J., Schumacher, A., Perez, K., Birnbaum, A., Reagan, J. L., Mega, A., Khurshid, H., Bartley, C., Lombardo, A., Rossiter, R., Papa, A., Bakalarski, P., Safran, H. Tags: Doctor-patient communication, Methodology, Access to care, Breast Cancer, Gastrointestinal, Genitourinary, H&N, Hematologic, Lung, Other, Sarcomas, Gene Expression and Profiling, Oncogenes CARE DELIVERY Source Type: research